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Abstract 
Catheter-related	arterial	thrombosis	(CAT)	are	increasingly	recognized	in	infants	and	
children.	Insufficient	data	are	available	on	the	incidence,	risk	factors,	treatment	and	
outcome	of	these	thrombotic	events.	This	work	provides	consensus	recommendations	
for	 future	 research	 on	 catheter-related	 arterial	 thrombosis	 in	 the	 paediatric	
population.	 In	 particular,	 future	 studies	 should	 distinguish	 between	 CAT	 due	 to	
indwelling	arterial	catheters	or	cardiac	catheterization	in	two	different	subpopulations	
(neonates	 and	 older	 children).	 Further	 studies	 should	 investigate	 sensitivity	 and	
specificity	of	clinical	signs	and	symptoms	for	early	screening	of	CAT	and	the	most	
appropriate	imaging	modality,	focusing	on	ultrasound	due	to	better	feasibility	in	the	
very	young	pediatric	population.	Adequately	powered,	well-designed	clinical	 trials	
should	 investigate	 efficacy	 and	 safety	 of	 different	 treatment	 and	 prevention	
strategies	as	well	as	the	risk	for	and	the	optimal	management	of	short-	and	long-term	
complications.
K E Y W O R D S
arterial	thrombosis,	catheter,	child,	pediatric
Essentials
•	 Arterial	clots	in	children	mostly	develop	from	indwelling	or	cardiac	catheters.
•	 Catheter-related	arterial	clots	can	cause	severe	immediate	and	long-term	complications.
•	 Only	sparse	data	from	clinical	trials	and	no	guidelines	on	optimal	diagnostic	and	treatment	modalities	are	available.
•	 The	present	work	provides	recommendations	for	dedicated	future	research	on	catheter-related	arterial	clots	in	children.
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1  | BACKGROUND AND RATIONALE
Catheter-	related	arterial	thrombosis	(CAT)	is	increasingly	recognized	
in	 children	 requiring	 monitoring	 in	 intensive	 care	 units	 or	 during	
surgery,	 and	 in	 children	 with	 congenital	 heart	 disease	 undergo-
ing	cardiac	catheterization.	CAT	can	cause	serious	acute	signs	and	
symptoms	but	also	 long-	term	complications	such	as	 leg	 length	dif-
ference,	claudication,	and	loss	of	arterial	access	for	future	diagnostic	
and therapeutic interventions.1-3	However,	there	remains	a	paucity	
of	data	from	well-	designed	studies	on	the	incidence,	risk	factors,	op-
timal	diagnosis	and	treatment	modalities,	outcomes,	and	prognostic	
factors	of	pediatric	CAT.
In	order	to	advance	knowledge	on	CAT	in	children,	the	Pediatric	
and	 Neonatal	 Thrombosis	 and	 Haemostasis	 Subcommittee	 of	 the	
International	 Society	 on	 Thrombosis	 and	 Hemostasis	 (ISTH)	 es-
tablished	 a	 pediatric	 CAT	Working	 Group	 in	 2013.	 Specific	 tasks	
of	 the	group	were	 to:	 systematically	 review	 the	existing	 literature	
on	pediatric	CAT;	identify	instances	of	heterogeneity	in	definitions	
employed	across	studies;	assess	gaps	in	knowledge;	and	make	rec-
ommendations	for	standardization	of	definitions	and	key	objectives	
for	 future	 research.	 The	 Working	 Group	 and	 collaborators	 have	
recently	completed	a	systematic	review	of	pediatric	CAT	 including	
studies	from	1945	to	2014,4	whose	key	findings	informed	the	pres-
ent	work,	and	are	summarized	below:
•	 Two	 types	of	 pediatric	CAT	were	distinguished:	 (A)	CAT	 from	
indwelling	 arterial	 catheters	 (IC-CAT,	 principally	 affecting	 ne-
onates)	 and	 (B)	 CAT	 from	 cardiac	 catheterization	 (CC-CAT,	
principally	 affecting	 neonates	 with	 known/suspected	 cardiac	
disease).
•	 The	cumulative	incidence	of	CAT	among	patients	with	indwelling	
arterial	catheters	(IC-CAT)	was	24%,	and	that	among	for	CC-CAT	
was	11%.	However,	incidence	rates	varied	widely	among	studies	
depending	on	whether	CAT	was	diagnosed	based	on	surveillance	
imaging	(including	both	symptomatic	and	asymptomatic	CAT)	or	
only	in	the	presence	of	clinical	signs	or	symptoms	(symptomatic	
CAT).
•	 Prematurity	(70%),	respiratory	distress	syndrome	(56%),	asphyxia	
(35%),	infection	(32%),	and	cardiac	disease	(33%)	were	commonly	
identified	 factors/co-morbidities	 associated	 with	 IC-CAT.	 Risk	
factors	 for	CC-CAT	 included	younger	age	and	body	weight	 less	
than	10	kg.
•	 While	CAT	was	frequently	diagnosed	by	Doppler	ultrasound,	and	
less	 commonly	by	 conventional	 angiography,	 studies	 comparing	
diagnostic	performance	among	these	and	other	imaging	modali-
ties	are	lacking.
•	 Antithrombotic	 treatment	 approaches	 varied	 widely	 between	 no	
antithrombotic	therapy,	the	use	of	anticoagulant	and/or	antiplatelet	
therapy,	and	acute	thrombolysis	or	thrombectomy.	Use	of	throm-
bolysis	(71%)	or	thrombectomy	(31%)	was	highly	prevalent	among	
published	studies,	also	potentially	reflecting	some	reporting	bias.
•	 With	regard	to	outcomes,	studies	have	mainly	focused	on	acute	
mortality	 (3%	 among	 prospective	 studies,	 including	 mortality	
attributed	 to	 underlying	 disease)	 and	 on	 thrombus	 resolution;	
data	on	long-term	outcomes	and	predictors	of	outcome	(by	which	
to	optimally	design	future	interventional	trials)	were	sparse,	even	
among	prospective	studies.
2  | METHODS
The recommendations provided here are based upon presentations 
made	 at	 the	Pediatric	 and	Neonatal	 Thrombosis	 and	Haemostasis	
Subcommittee	 meetings	 held	 during	 the	 2014,	 2015,	 and	 2016	
meetings	of	the	ISTH.	The	pediatric	CAT	Working	Group	was	com-
prised	 of	M.	 Albisetti	 (Working	 Group	 lead),	 N.	 Goldenberg	 (SSC	
subcommittee	 co-	chair	 representative),	M.	 Rizzi,	M.	 Bonduel,	 and	
S.	Revel-	Vilk.
3  | RECOMMENDATIONS
1.	 Future	 studies	 should	 better	 distinguish	 patients	 with	 IC-CAT	
and	 patients	 with	 CC-CAT,	 in	 order	 to	 achieve	 greater	 stan-
dardization	 in	 disease/subpopulation	 definitions.	 This	 will	 limit	
heterogeneity	across	studies,	permitting	more	robust	meta-anal-
yses in the future.
2. Given the substantive mortality and potential morbidities associ-
ated	with	pediatric	CAT—yet	the	significant	 limitations	in	current	
knowledge	of	risk	factors,	optimal	diagnosis	and	treatment	strate-
gies,	treatment-outcomes	relationships	and	other	prognostic	fac-
tors—a	high	priority	should	be	placed	on	the	design	and	conduct	of	
cooperative prospective cohort and interventional studies in pedi-
atric	CAT.	Specific	study	aims/investigations	should	evaluate:	
a.	 The	sensitivity	and	specificity	of	early	 screening	 for	CAT	by	
means	of	clinical	signs	and	symptoms	compared	with	Doppler	
ultrasonography.
b.	 The	most	appropriate	imaging	modality,	in	terms	of	sensitivity,	
specificity and acceptability in neonates and children. Studies 
should	 focus	 on	 ultrasound,	which	 is	 noninvasive	 and	more	
feasible	 in	 the	 very	 young	 population	 rather	 than	magnetic	
resonance	 angiography	 or	 conventional	 angiography,	 and	
avoids	the	radiation	exposure	of	computed	tomography	with	
angiography.
c.	 Risk	 factors	 for	 CAT	 including,	 for	 example,	 duration	 of	
catheter	 insertion,	 catheter	 type,	 and	 thrombophilia	 labo-
ratory	 testing	 findings.	 Studies	 should	 focus	 on	 establish-
ing	 predictors	 of	 poor	 outcome	 and	 the	 role	 of	 targeted	
prophylaxis.
d.	 Short-term	 outcome	 (including	 limb	 ischemia,	 amputation,	
skin	 necrosis)	 in	 neonates	 and	 children	 with	 IC-CAT	 and	
CC-CAT	 as	 such	 acute	 symptoms	 may	 require	 aggressive	
therapeutic	 intervention	 and	greatly	 impact	morbidity	 and	
mortality.
e.	 Long-term	 outcomes	 (including	 functional	 outcomes	 and	
quality	of	life)	as	well	as	predictors	of	outcome	in	neonates	
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and	 children	 with	 IC-CAT	 and	 CC-CAT.	 As	 children	 grow	
and	 mature	 through	 the	 developmental	 stages,	 it	 will	 be	
useful	to	develop,	adapt,	and	validate	specific	instruments/
measures	relevant	to	the	sequelae	of	CAT	for	different	pe-
diatric	age	groups.	In	turn,	findings	on	outcomes	and	prog-
nostic stratification from such studies will be critical to the 
optimal	design	of	future	interventional	trials	in	IC-CAT	and	
CC-CAT.
f.	 The	 optimal	 intensity,	 duration,	 and	 modality	 of	 antithrom-
botic	therapy,	 including	thrombolysis	and	thrombectomy,	for	
IC-CAT	 and	 CC-CAT	 in	 children.	 Rather	 than	 extrapolation	
from	adult	practice,	 this	will	 require	the	conduct	of	well-de-
signed,	pediatric	clinical	trials	that	are	adequately	powered	to	
determine	 differences	 in	 efficacy	 and	 safety,	 including	 both	
short-	and	long-term	outcomes.
g.	 Optimal	prevention	strategies	against	 IC-CAT	and	CC-CAT	
in	children.	This	 too,	will	 require	devoted	pediatric	clinical	
trials powered to demonstrate comparative efficacy and 
safety.
3. Definitions of primary and secondary outcome measures to be 
employed	in	future	studies	investigating	diagnostic,	treatment,	
and	 long-term	 complications	 of	CAT	 should	 be	 standardized.	
This	 approach	 will	 require	 interdisciplinary	 cooperation	 in	
order	to	cover	all	specific	needs	and	features	of	newborns,	and	
will	permit	comparisons	across	studies.	Following	the	model	of	
the previously published communication of the SSC on effi-
cacy and safety endpoints for clinical trials in deep vein throm-
bosis	 in	 children,5	 the	Working	Group	 recommends	adopting	
the	 outcome	 definitions	 in	 pediatric	 CAT	 clinical	 research	
listed in Table 1.
4  | DISCUSSION
The present recommendations represent an effort to provide 
evidence-	based	 guidelines	 for	 CAT	 in	 children	 as	 an	 emerging	
complication	 of	 pediatric	 tertiary	 care	 associated	 with	 significant	
morbidity	and	mortality.	Three	major	key	points	from	these	recom-
mendations warrant emphasis and discussion.
CAT	mostly	affects	neonates	and	very	young	infants	with	severe	
medical	 conditions—a	 very	 particular	 vulnerable	 population.	 Trial	
designs	 and	 standardization	 of	 definitions	 in	CAT	will	 have	 to	 ad-
dress	the	specific	features	and	needs	of	this	very	young	and	often	
medically	complex	population.	In	particular,	trials	assessing	optimal	
intensity,	duration,	and	modality	of	antithrombotic	therapy	and	op-
timal	prevention	strategies	may	warrant	adaptation	of	primary	and	
secondary outcome measures.
The	 recommended	 future	 research	 strategy	 will	 investigate	
two	 type	 of	 CAT,	 involving	 two	 different	 subpopulations.	While	
IC-	CAT	occurs	in	neonates	and	young	infants	with	several	under-
lying	diseases	treated	in	intensive	care	units,	CC-	CAT	will	involve	
neonates	 and	 young	 infants	 undergoing	 cardiac	 catheterization	
for	 congenital	heart	disease.	 It	 is	 anticipated	 that	 recommended	
studies may warrant inclusion of different/additional objectives. 
In	specific	regard	to	IC-	CAT,	additional	partnership	with	the	ISTH	
should	be	 sought	between	pediatric	 intensivists,	 especially	 neo-
natology	societies.	For	CC-	CAT,	partnership	with	the	ISTH	should	
be	 sought	 from	 pediatric	 cardiology	 and	 cardiothoracic	 surgery	
societies.
The	 recruitment	of	very	young	children	 in	 interventional	 trials	 is	
more	challenging	than	for	adults	or	older	children	because	of	the	even	
greater	perceived	vulnerability	of	infants,	and	hence	an	understandable	
Endpoints Primary outcome Secondary outcome
Efficacy •	 Contiguous	progression	or	
recurrence
•	 Degree	of	radiological	resolution	over	time
•	 CAT-specific	and	all-cause	mortalities
•	 Sequelae	of	arterial	insufficiency	(limb	
shortening/atrophy,	claudication,	
amputation)	over	the	pediatric	age	span
•	 Functional	outcomes	(QoL)
Safety •	 Major	bleeding:
–	 fatal	bleeding
–	 bleeding	with	decrease	in	
Hgb	≥	20	g	L−1	in	a	24-h	
period
–	 retroperitoneal	bleeding
–	 intracerebral	bleeding
–	 bleeding	requiring	surgical	
intervention	in	operating	
rooms
•	 CRNM	bleeding:
–	 overt	bleed	requiring	blood	product	
transfusion,	not	directly	attributable	to	the	
patient’s	underlying	condition
–	 bleeding	requiring	medical	or	surgical	
intervention	to	restore	hemostasis,	other	
than	in	operating	rooms
–	 Other	bleeding	for	which	medical	
attention	has	been	sought	(e.g.,	emergency	
department,	urgent	care,	or	non-routine	
outpatient	clinic	visit)
•	 Minor	bleeding:
– any overt macroscopic evidence of 
bleeding	not	fulfilling	above	criteria	for	
major	or	clinical	relevant	bleeding
CAT,	catheter-	related	arterial	thrombosis;	CRNM,	clinically	relevant,	non-	major;	Hgb,	hemoglobin;	
QoL,	quality	of	life.
TABLE  1 Definitions of primary and 
secondary outcome measures in pediatric 
CAT
196  |     ALBISETTI ET AL.
reticence of parents and clinicians to enroll infants on trials that are 
deemed	to	pose	more	than	minimal	 risk.	Collaborative	multinational	
groups	and/or	pediatric	clinical	trials	networks	that	pool	quality	data	
and	 resources	 are	 therefore	 an	 essential	 strategy	 to	 overcome	 the	
problem	of	underpowered	trials	due	to	low	accrual	in	young	children.	
In	addition,	a	prioritization	strategy	of	recommended	studies	starting	
from	 rigorously	designed	 and	executed	multicenter	 pediatric	 cohort	
studies	that	deeply	characterize	pediatric	CAT	(patient	demographics	
and	comorbidities,	diagnostic	features	of	thrombosis,	treatments	and	
durations	administered,	short-	and	long-	term	outcomes,	and	prognos-
tic	 factors)	will	 inform	the	design	and	conduct	of	 risk-	stratified	 ran-
domized	trials	on	treatment	and	prophylaxis	of	CAT.6
In	conclusion,	this	article	provides	consensus	recommendations	
for	 future	 research	 in	 pediatric	 CAT.	 These	 recommendations	will	
need to be updated as evidence accrues and interdisciplinary collab-
orations ensue.
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